Baseline characteristics in the recurrent AMI cohort compared to patients without recurrent AMI and 1-year all-cause mortality rates
| Variable, n (%) | Recurrent AMI cohort | Patients without recurrent AMI | P value* |
| N=432 | N=7035 | ||
| Age, median (IQR) | 69 (13) | 66 (15) | <0.0001 |
| Age group | |||
| <35 years | 2 (0.5) | 30 (0.4) | <0.0001 |
| 35–49 years | 18 (4.2) | 658 (9.4) | |
| 50–64 years | 127 (29.4) | 2654 (37.7) | |
| 65–80 years | 285 (66.0) | 3693 (52.5) | |
| Female, n (%) | 126 (29.2) | 1711 (24.3) | 0.0232 |
| Type of AMI | |||
| Type 1 AMI | 377 (87.3) | 6413 (91.2) | 0.0032 |
| Type 2 AMI | 23 (5.3) | 203 (2.9) | |
| Type 3–5 AMI | 0 (0) | 329 (4.7) | |
| Data not available in SWEDEHEART | 32 (7.4) | 90 (1.3) | |
| NSTEMI/STEMI classification | |||
| NSTEMI | 335 (77.5) | 5075 (72.1) | 0.0023 |
| STEMI | 73 (16.9) | 1652 (23.5) | |
| Data not available in SWEDEHEART | 24 (5.6) | 308 (4.4) | |
| Arrived at ED by ambulance | 249 (57.6) | 3346 (47.6) | <0.0001 |
| Index AMI coronary reperfusion (PCI or CABG) | 192 (44.4) | 5402 (76.8) | <0.0001 |
| Comorbidities recorded at index AMI | |||
| Diabetes | 152 (35.2) | 1207 (17.2) | <0.0001 |
| History of prior AMI | 129 (29.9) | 946 (13.4) | <0.0001 |
| Heart failure | 39 (9.0) | 205 (2.9) | <0.0001 |
| History of prior stroke | 33 (7.6) | 317 (4.5) | 0.0028 |
| Chronic kidney disease | 32 (7.4) | 169 (2.4) | <0.0001 |
| Peripheral arterial disease | 26 (6.0) | 92 (1.3) | <0.0001 |
| Medication prescribed at index AMI discharge and continued for≥6 months | |||
| Aspirin | 403 (93.3) | 6615 (94.0) | 0.5285 |
| P2Y12 inhibitors† | 396 (91.7) | 6409 (91.1) | 0.6884 |
| Clopidogrel | 264 (61.1) | 3291 (46.8) | <0.0001 |
| Prasugrel | 16 (3.7) | 89 (1.3) | <0.0001 |
| Ticagrelor | 166 (38.4) | 3387 (48.1) | <0.0001 |
| Beta blockers | 409 (94.7) | 6571 (93.4) | 0.2988 |
| ACE inhibitors/ARB | 359 (83.1) | 5705 (81.1) | 0.2999 |
| Statins | 397 (91.9) | 6684 (95.0) | 0.0046 |
| 1-year all-cause mortality following index AMI discharge | 50 (11.6) | 179 (2.5) | p<0.0001 |
*Continuous variables compared with the Median test and categorical variables compared with the χ2 test.
†Some patients switched between different types of P2Y12 inhibitors during the study period.
ACE/ARB, angiotensin-converting enzyme/angiotensin II receptor blockers; AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; ED, emergency department; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; SWEDEHEART, Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies Registry.